Fedratinib and Tezacaftor and Ivacaftor
Determining the interaction of Fedratinib and Tezacaftor and Ivacaftor and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.ADJUST DOSE: Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme. In study subjects, ivacaftor peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 2.5- and 3.0-fold when it was administered concomitantly with fluconazole, a moderate CYP450 3A4 inhibitor. When lumacaftor/ivacaftor was coadministered with ciprofloxacin, another moderate CYP450 3A4 inhibitor, lumacaftor Cmax and AUC decreased by 12% and 14%, respectively, while ivacaftor Cmax and AUC increased by 29% each. These changes are not considered clinically significant. Physiologically based pharmacokinetic (PBPK) simulations suggest that coadministration with moderate CYP450 3A4 inhibitors may increase elexacaftor AUC by 1.9- to 2.3-fold and tezacaftor AUC by approximately 2.1-fold. MANAGEMENT: Please consult manufacturer's product labeling for complete dosing information. For ivacaftor - The dosage for patients 6 years or older should be reduced to 150 mg once daily when used with moderate CYP450 3A4 inhibitors (2 to
Professional:ADJUST DOSE: Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme. In study subjects, ivacaftor peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 2.5- and 3.0-fold when it was administered concomitantly with fluconazole, a moderate CYP450 3A4 inhibitor. When lumacaftor/ivacaftor was coadministered with ciprofloxacin, another moderate CYP450 3A4 inhibitor, lumacaftor Cmax and AUC decreased by 12% and 14%, respectively, while ivacaftor Cmax and AUC increased by 29% each. These changes are not considered clinically significant. Physiologically based pharmacokinetic (PBPK) simulations suggest that coadministration with moderate CYP450 3A4 inhibitors may increase elexacaftor AUC by 1.9- to 2.3-fold and tezacaftor AUC by approximately 2.1-fold.
MANAGEMENT: Please consult manufacturer's product labeling for complete dosing information.
For ivacaftor - The dosage for patients 6 years or older should be reduced to 150 mg once daily when used with moderate CYP450 3A4 inhibitors (2 to
- "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
- "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
- "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
Generic Name: ivacaftor / tezacaftor
Brand name: Symdeko, Symdeko 4-Week
Synonyms: Ivacaftor and tezacaftor
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Fedratinib-Tezacaftor/ivacaftor and ivacaftor
- Fedratinib-TGQ 30PSE/3BRM/15DM
- Fedratinib-TGQ 7.5PEH/4BRM/15DM
- Fedratinib-TGT First Aid Antibiotic
- Fedratinib-TGT First Aid Cleansing
- Fedratinib-TH Antibiotic + Pain Relief
- Tezacaftor and Ivacaftor-Fedratinib Hydrochloride
- Tezacaftor and Ivacaftor-Feiba
- Tezacaftor and Ivacaftor-Feiba NF
- Tezacaftor and Ivacaftor-Feiba VH Immuno
- Tezacaftor and Ivacaftor-Feiba-VH
- Tezacaftor and Ivacaftor-Felbamate